Mechanism of Action and Clinical Effects of Metformin

Primary Mechanisms

Metformin's major glucose-lowering effect occurs through suppression of hepatic glucose output, particularly by reducing gluconeogenesis, which is responsible for lowering fasting glycemia in patients with type 2 diabetes, according to the American Diabetes Association 1

Metformin does not increase insulin secretion—insulin levels remain unchanged or may actually decrease during treatment, as stated by the American Association of Clinical Endocrinologists 2
Metformin monotherapy does not cause hypoglycemia because it does not stimulate insulin release, as recommended by the American College of Clinical Endocrinology 2

Metformin typically reduces HbA1c by 1.0-1.5 percentage points when used as monotherapy in patients with type 2 diabetes, with a moderate strength of evidence, according to the American Diabetes Association 1
The drug is weight-neutral or promotes modest weight loss, contrasting with many other glucose-lowering medications, with a low strength of evidence, as reported by the National Institute of Diabetes and Digestive and Kidney Diseases 1

Metformin improves cellular metabolism in a blood glucose-independent manner, with a high strength of evidence, as demonstrated by the European Association for the Study of Diabetes 3
The UK Prospective Diabetes Study demonstrated that metformin-treated patients had better clinical outcomes than insulin-treated patients despite similar glucose control, indicating favorable metabolic effects beyond glycemic reduction, with a high strength of evidence, as published by the European Association for the Study of Diabetes 3

Metformin can be safely used with estimated glomerular filtration rate ≥30 mL/min/1.73 m², as recommended by the National Kidney Foundation 2
Long-term metformin use may cause vitamin B12 deficiency through interference with absorption, with a moderate strength of evidence, as reported by the American College of Clinical Endocrinology 1

Activating AMPK (adenosine monophosphate-activated protein kinase) in hepatocytes, which inhibits fatty acid synthesis and further suppresses gluconeogenesis, is a key mechanism by which metformin increases insulin sensitivity, as noted by the Clinical and Molecular Hepatology 4